Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10046165 | 0.91 | MAOB (0.72) | MAOBMEN1KMT2AALOX5 | |
| SCHEMBL23906959 | 0.91 | MAOB (0.79) | MAOBMEN1KMT2AABCB1APP | |
| SCHEMBL308991 | 0.87 | MAOB (0.72) | MAOBMEN1KMT2AALOX5BCHE | |
| SCHEMBL21582181 | 0.85 | MAOB (0.65) | MAOBMEN1KMT2AABCB1APP | |
| SCHEMBL31644032 | 0.84 | MAOB (0.69) | MAOBMEN1KMT2AABCB1APP | |
| SCHEMBL5791635 | 0.84 | MAOB (0.69) | MAOBMEN1KMT2AABCB1APP | |
| SCHEMBL16551002 | 0.83 | MAOB (0.67) | MAOBMEN1KMT2AABCB1APP | |
| SCHEMBL16551263 | 0.83 | MAOB (0.67) | MAOBMEN1KMT2AABCB1APP | |
| SCHEMBL4073348 | 0.83 | MAOB (0.62) | MAOBMEN1KMT2AALOX5 | |
| SCHEMBL13703986 | 0.83 | MAOB (0.67) | MAOBMEN1KMT2AABCB1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018030550-A1 | HETEROCYCLIC COMPOUNDS WITH AN ROR(GAMMA)T MODULATING ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-15 | — | — | WO | disclosed |
| EP-0975629-A4 | TREATMENT OR PROPHYLAXIS OF PROSTATIC CANCER AND BENIGN PROSTATIC HYPERPLASIA WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-0986556-A4 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-0986556-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2000-03-22 | — | — | EP | disclosed |
| EP-0975629-A1 | TREATMENT OR PROPHYLAXIS OF PROSTATIC CANCER AND BENIGN PROSTATIC HYPERPLASIA WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| US-5919800-A | INHIBITING ENDOMETRIOSIS BY ADMISTERING (6-HYDROXY-3-(4-(2-(1-PIPERIDINYL)ETHOXY)PHENOXY)-2-(4-METHOXYPHENYL))BENZO B)THIOPHENE OR THE HYDROCHLORIDE SALT THEREOF | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | disclosed |
| US-5856339-A | POST-MENOPAUSAL SYNDROME, AND UTERINE FIBROID DISEASE, ENDOMETRIOSIS, AND AORTAL SMOOTH MUSCLE CELL PROLIFERATION. | ELI LILLY AND COMPANY (US) | 1999-01-05 | — | — | US | disclosed |
| US-5856340-A | 2-PHENYL-3-/ALKOXYPHENOXY OR PHENYLTHIO/BENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 1999-01-05 | — | — | US | disclosed |
| WO-1998045287-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998045288-A1 | TREATMENT OR PROPHYLAXIS OF PROSTATIC CANCER AND BENIGN PROSTATIC HYPERPLASIA WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 1998-10-15 | — | — | WO | disclosed |
| US-5723474-A | TREATING POST-MENOPAUSAL SYNDROME, UTERINE FIBROID DISEASE, ENDOMETRIOSIS, AND AORTAL SMOOTH MUSCLE CELL PROLIFERATION; ANTIESTROGENS | ELI LILLY AND COMPANY (US) | 1998-03-03 | — | — | US | disclosed |